Evidence map›Paper›PMID 31682641›Full record

ArticlePLoS pathogens2019

The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response.

Leon Louis Seifert, Clara Si, Debjani Saha, Mohammad Sadic, Maren de Vries, Sarah Ballentine, Aaron Briley, Guojun Wang, Ana M Valero-Jimenez, Adil Mohamed and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Leon Louis SeifertLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, United States of America.ORCID 0000-0002-0089-7669
Clara SiDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.ORCID 0000-0003-3781-2654
Debjani SahaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Mohammad SadicDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.ORCID 0000-0002-4728-8908
Maren de VriesDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.ORCID 0000-0003-1059-8344
Sarah BallentineDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.
Aaron BrileyDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.ORCID 0000-0002-5722-2777
Guojun WangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Ana M Valero-JimenezDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.
Adil MohamedDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.ORCID 0000-0003-0080-2727
Uwe SchaeferLaboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, New York, United States of America.
Hong M MoultonCarlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, United States of America.ORCID 0000-0002-8095-1513
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Shashank TripathiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Brad R RosenbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Meike DittmannDepartment of Microbiology, New York University School of Medicine, New York, New York, United States of America.ORCID 0000-0002-1741-7916
New York University · USIcahn School of Medicine at Mount Sinai · USRockefeller University · USIndian Institute of Science Bangalore · INOregon State University · US

Funding

SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
INFECTIOUS DISEASES &BASIC MICROBIOLOGICAL MECHANISMST32AI007180 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 1985 to 2022
$8.9M
Type I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5M
ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activityR01AI143639 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 2019 to 2023
$2.5M
Immune profiling by high throughput sequencing of complete antigen receptorsDP5OD012142 · OD · ROCKEFELLER UNIVERSITY · PI ROSENBERG, BRAD · 2012 to 2016
$2.1M
Transforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9M
Intrinsic and innate barriers to respiratory virus infectionsR00AI121473 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DITTMANN, MEIKE · 2017 to 2018
$498k
Intrinsic and innate barriers to respiratory virus infectionsK99AI121473 · NIAID · ROCKEFELLER UNIVERSITY · PI DITTMANN, MEIKE · 2016 to 2016
$59k
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS K99 AI121473NIAID NIH HHS R00 AI121473NIAID NIH HHS R01 AI091707NIAID NIH HHS R01 AI143639NIAID NIH HHS T32 AI007180NIAID NIH HHS U19 AI135972NIH HHS DP5 OD012142NIH HHS S10 OD018522
6 · The paper itself

Abstract

Induction of vast transcriptional programs is a central event of innate host responses to viral infections. Here we report a transcriptional program with potent antiviral activity, driven by E74-like ETS transcription factor 1 (ELF1). Using microscopy to quantify viral infection over time, we found that ELF1 inhibits eight diverse RNA and DNA viruses after multi-cycle replication. Elf1 deficiency results in enhanced susceptibility to influenza A virus infections in mice. ELF1 does not feed-forward to induce interferons, and ELF1's antiviral effect is not abolished by the absence of STAT1 or by inhibition of JAK phosphorylation. Accordingly, comparative expression analyses by RNA-seq revealed that the ELF1 transcriptional program is distinct from interferon signatures. Thus, ELF1 provides an additional layer of the innate host response, independent from the action of type I interferons.

Indexed as

A549 CellsAnimalsAntiviral AgentsFemaleGene Expression RegulationHumansImmunity, InnateInfluenza A virusInterferon Type IMiceMice, Inbred C57BLNF-kappa BNuclear ProteinsOrthomyxoviridae InfectionsPhosphorylationSignal TransductionAntiviral AgentsELF1 protein, humanInterferon Type INF-kappa BNuclear ProteinsSTAT1 protein, humanSTAT1 Transcription FactorTranscription Factors

Identifiers

PMID31682641
PMCPMC6932815
OpenAlexW2988085959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.